These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 5051364)

  • 21. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progesterone-controlled growth hormone overproduction and naturally occurring canine diabetes and acromegaly.
    Eigenmann JE; Eigenmann RY; Rijnberk A; van der Gaag I; Zapf J; Froesch ER
    Acta Endocrinol (Copenh); 1983 Oct; 104(2):167-76. PubMed ID: 6227190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.
    Yen SS; Siler TM; DeVane GW
    N Engl J Med; 1974 Apr; 290(17):935-8. PubMed ID: 4593614
    [No Abstract]   [Full Text] [Related]  

  • 24. GH response to oral and intravenous glucose load in acromegalic patients.
    Mancini A; Zuppi P; Fiumara C; Valle D; Conte G; Fabrizi ML; Sammartano L; Anile C; Maira G; De Marinis L
    Horm Metab Res; 1995 Jul; 27(7):322-5. PubMed ID: 7590615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of acromegaly using CB-154 and medroxy-progesterone acetate].
    Ichikawa Y; Yoshida K; Kawagoe M
    Horumon To Rinsho; 1977 Dec; 25(12):1303-4. PubMed ID: 598028
    [No Abstract]   [Full Text] [Related]  

  • 26. Secretin and insulin release in acromegaly.
    Chisholm DJ; Lazarus L; Young JD
    J Clin Endocrinol Metab; 1972 Jul; 35(1):108-12. PubMed ID: 5032508
    [No Abstract]   [Full Text] [Related]  

  • 27. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly.
    Hattori N; Shimatsu A; Kato Y; Koshiyama H; Ishikawa Y; Assadian H; Tanoh T; Nagao M; Imura H
    J Clin Endocrinol Metab; 1990 Mar; 70(3):771-6. PubMed ID: 2106529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progestins in the medical management of active acromegaly.
    Lawrence AM; Kirsteins L
    J Clin Endocrinol Metab; 1970 May; 30(5):646-52. PubMed ID: 5462817
    [No Abstract]   [Full Text] [Related]  

  • 30. Bromocriptine reduces growth hormone in acromegaly.
    Bell PM; Atkinson AB; Hadden DR; Kennedy L; Leslie H; Merrett JD; Sheridan B
    Arch Intern Med; 1986 Jun; 146(6):1145-9. PubMed ID: 3718102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
    Giustina A; Bresciani E; Bussi AR; Bollati A; Bonfanti C; Bugari G; Chiesa L; Giustina G
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1333-40. PubMed ID: 7536207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of medroxyprogesterone acetate (Provera) on plasma growth hormone levels and on carbohydrate metabolism. II. Studies in the ovariohysterectomized, oestradiol-primed bitch.
    Eigenmann JE; Eigenmann RY
    Acta Endocrinol (Copenh); 1981 Dec; 98(4):603-8. PubMed ID: 6458193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats.
    Winneker RC; Parsons JA
    Cancer Res; 1981 May; 41(5):1772-7. PubMed ID: 7214344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for higher proportion of "little" growth hormone with increased radioreceptor activity in acromegalic plasma.
    Gorden P; Lesniak MA; Eastman R; Hendricks CM; Roth J
    J Clin Endocrinol Metab; 1976 Aug; 43(2):364-73. PubMed ID: 950368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum-insulin in acromegaly.
    Elkeles RS; Wright AD; Lowy C; Fraser TR
    Lancet; 1969 Sep; 2(7621):615-8. PubMed ID: 4185594
    [No Abstract]   [Full Text] [Related]  

  • 36. [STH blood level after metopirone in 12 patients with acromegaly].
    Chiodini PG; Liuzzi A; Spinelli F; Botalla L; Silvestrini F
    Ann Endocrinol (Paris); 1972; 33(4):431-5. PubMed ID: 4664004
    [No Abstract]   [Full Text] [Related]  

  • 37. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses.
    Liuzzi A; Chiodini PG; Botalla L; Silvestrini F; Müller EE
    J Clin Endocrinol Metab; 1974 Nov; 39(5):871-6. PubMed ID: 4214404
    [No Abstract]   [Full Text] [Related]  

  • 38. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
    Losa M; Schopohl J; König A; Müller OA; von Werder K
    J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.